Código QR (código de barras bidimensional)

Successful Dostarlimab Rechallenge Following Pembrolizumab‐Induced Autoimmune Hemolytic Anemia: A Case Report

ABSTRACT Immune checkpoint inhibitors (ICIs) have revolutionized cancer treatment, offering durable responses across multiple malignancies. However, these agents can trigger severe immune‐related adverse events (irAEs), including drug‐induced autoimmune hemolytic anemia (AIHA), which often necessita...

ver descrição completa

Na minha lista:
Principais autores: Zaid Khamis, Kai Wang, Mohammad Aldalahmeh, Salim Barakat, Nawaraj Adhikari, Raghad Khassawneh, Bhavya Misri, Dhar Meekoo
Formato: Artigo
Idioma:Inglês
Publicado em: Wiley 2025-08-01
coleção:Clinical Case Reports
Assuntos:
adverse immune events
autoimmune hemolytic anemia
checkpoint inhibitor rechallenge
dostarlimab
immune checkpoint inhibitors
pembrolizumab
Acesso em linha:https://doi.org/10.1002/ccr3.70776
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registros relacionados